THORLNC and breast carcinoma: To assess if a THOR signature is observed in breast cancer, the CpG site within THOR targeted by the probe cg11625005 (Fig. 1A) was analyzed in the breast invasive carcinoma cohort from TCGA (n = 841, Fig. 1).